Robert Monaghan, the new CEO of Zyomyx, wants to transform the protein biochip company into a real commercial organization.
Yes, the company already has a protein profiling biochip system on the market: The system, which can process 12 chips at once and includes a scanner and data-analysis software, was launched in February, along with a human cytokine profiling chip. Zyomyx also has customers, including Aventis, GlaxoSmithKline, and Partners Healthcare
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.